Lifecore Biomedical, Inc. (LFCR) Income Statement
LFCR FY2026 at a glance
Fiscal year ended May 31, 2026 · U.S. dollarsLFCR revenue and net income
Where LFCR's revenue goes
FY2026Each bar shows an amount and its share of revenue. LFCR kept −23.8% of revenue as net income.
LFCR profit margins
LFCR growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.5% | +5.2% | +5.1% | −13.3% |
| Gross profit | +0.8% | +1.3% | +0.8% | −5.4% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LFCR quarterly EPS vs estimates
Lifecore Biomedical beat the analyst EPS estimate in 3 of the last 8 quarters.
LFCR income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $129.5M | $128.9M | $128.3M | $111.3M | $185.8M | $100.9M | $160.1M | $557.6M | $524.2M | $532.3M |
| Cost of revenue | $88.9M | $88.6M | $86.4M | $72.2M | $135.4M | $61.9M | $120.7M | $476.6M | $445.9M | $449.1M |
| Gross profit | $40.6M | $40.3M | $41.9M | $39.1M | $50.4M | $38.9M | $39.4M | $81.0M | $78.3M | $83.2M |
| Research & development | $8.5M | $8.3M | $8.6M | $7.8M | $7.8M | $6.7M | $7.6M | $11.5M | $12.8M | $9.5M |
| Sales, general & admin | — | $44.0M | $43.0M | $42.6M | $46.1M | $65.3M | $72.1M | $64.1M | $52.0M | $58.2M |
| Total operating expenses | $41.9M | $57.5M | $50.7M | $50.9M | $54.0M | $47.8M | $65.3M | $75.5M | $64.8M | $67.7M |
| Operating income | −$1.3M | −$17.2M | −$8.8M | −$11.8M | −$3.6M | −$8.8M | −$25.9M | −$8.0M | $11.8M | $15.5M |
| Interest income | — | $333,000 | $58,000 | $68,000 | $81,000 | $48,000 | $103,000 | $145,000 | — | — |
| Interest expense | $2.2M | $21.8M | $18.1M | $15.6M | $17.4M | $8.9M | $4.6M | $5.2M | $1.9M | $1.8M |
| Income before taxes | −$30.2M | −$38.7M | $9.5M | −$20.7M | −$52.1M | −$29.8M | −$30.6M | $3.6M | $16.4M | $15.0M |
| Income taxes | $577,714 | $43,000 | $183,000 | −$5.2M | −$5.8M | −$6.3M | −$8.8M | $1.5M | −$9.4M | $4.3M |
| Net income | −$30.8M | −$38.7M | $12.0M | −$116.7M | −$97.4M | −$32.3M | −$38.2M | $2.1M | $24.8M | $10.6M |
| EBITDA | $8.2M | −$8.8M | $35.6M | $12.8M | −$68.0M | −$987,000 | −$7.2M | $23.5M | $25.0M | $26.7M |
| EPS (diluted) | −$0.78 | −$1.14 | −$1.07 | −$1.06 | −$0.54 | −$0.48 | −$0.66 | $0.02 | $0.43 | $0.44 |
| Gross margin | 31.4% | 31.3% | 32.6% | 35.1% | 27.1% | 38.6% | 24.6% | 14.5% | 14.9% | 15.6% |
| Operating margin | −1.0% | −13.4% | −6.9% | −10.6% | −1.9% | −8.7% | −16.2% | −1.4% | 2.3% | 2.9% |
| Net margin | −23.8% | −30.0% | 9.4% | −104.9% | −52.4% | −32.0% | −23.9% | 0.4% | 4.7% | 2.0% |
| May '26 | Feb '26 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | Aug '23 | May '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.2M | $23.2M | $31.1M | $36.4M | $35.2M | $32.6M | $24.7M | $37.9M | $25.5M | $30.1M | $24.5M | $26.5M |
| Cost of revenue | $22.1M | $18.7M | $23.3M | $22.5M | $25.3M | $21.5M | $19.3M | $20.6M | $17.1M | $20.2M | $21.8M | $18.0M |
| Gross profit | $12.1M | $4.5M | $7.8M | $14.0M | $9.8M | $11.1M | $5.4M | $17.3M | $8.4M | $10.0M | $2.7M | $8.5M |
| Research & development | $1.5M | $1.2M | $2.0M | $2.1M | $2.0M | $1.9M | $2.2M | $2.2M | $2.6M | $2.1M | $2.1M | $2.2M |
| Sales, general & admin | $8.0M | $7.9M | $8.9M | $9.0M | $10.1M | $11.1M | $14.3M | $12.2M | $11.7M | $9.3M | $9.2M | $11.0M |
| Total operating expenses | $9.5M | $9.1M | $10.9M | $8.7M | $18.9M | $13.0M | $17.0M | $15.1M | $9.6M | $31.6M | $33.1M | $15.1M |
| Operating income | $2.6M | −$4.7M | −$3.1M | $5.3M | −$9.0M | −$2.0M | −$11.6M | $2.1M | −$1.2M | −$1.5M | −$8.6M | −$6.5M |
| Interest income | $144,000 | $128,000 | $58,000 | — | $108,000 | — | $15,000 | — | — | — | — | $15,000 |
| Interest expense | $7.8M | $7.3M | $6.4M | $5.5M | $5.5M | $5.5M | $5.4M | $5.8M | $3.9M | $4.1M | $3.9M | $4.8M |
| Income before taxes | −$6.1M | −$14.9M | −$9.7M | −$1.1M | −$14.8M | −$6.5M | −$16.3M | −$7.1M | −$29.3M | $14.2M | −$12.5M | −$11.3M |
| Income taxes | $23,000 | $43,000 | $333,000 | $33,000 | −$8,000 | $43,000 | −$25,000 | −$57,000 | $230,000 | — | — | $70,000 |
| Net income | −$6.2M | −$15.0M | −$10.0M | −$1.1M | −$14.8M | −$6.6M | −$16.2M | −$7.1M | −$35.6M | $14.2M | −$10.8M | −$36.5M |
| EBITDA | $4.1M | −$5.3M | −$7.1M | $6.3M | −$7.2M | $981,000 | −$8.9M | $899,000 | −$22.5M | — | — | −$3.2M |
| EPS (diluted) | −$0.19 | −$0.16 | −$0.43 | −$0.10 | −$0.47 | −$0.20 | −$0.37 | −$0.17 | $0.42 | −$0.13 | −$1.19 | −$0.11 |
| Gross margin | 35.3% | 19.2% | 25.0% | 38.4% | 28.0% | 34.0% | 21.8% | 45.6% | 33.0% | 33.0% | 11.1% | 32.2% |
| Operating margin | 7.5% | −20.1% | −9.9% | 14.6% | −25.7% | −6.0% | −46.9% | 5.7% | −4.8% | −4.9% | −35.2% | −24.6% |
| Net margin | −18.0% | −64.6% | −32.1% | −3.1% | −42.0% | −20.2% | −65.7% | −18.7% | −139.4% | 47.2% | −43.9% | −137.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LFCR's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LFCR financial results
In fiscal year 2026 (ended May 31, 2026), Lifecore Biomedical reported revenue of $129.5 million, up 0.5% from the year before. It had a net loss of $30.8 million, a net profit margin of −23.8%. Diluted earnings per share came to −$0.78. Over five years revenue grew at an average rate of 5.1% a year.
See the LFCR stock overview for the latest quote and news, or the LFCR chart for price history and technical indicators.
LFCR income statement FAQ
What is Lifecore Biomedical's annual revenue?
Lifecore Biomedical reported total revenue of $129.5 million for fiscal year 2026, which ended on May 31, 2026. That was up 0.5% from $128.9 million the previous year.
Is Lifecore Biomedical profitable?
No. Lifecore Biomedical reported a net loss of $30.8 million in fiscal 2026, a net profit margin of −23.8%; its operating margin was −1.0%.
What is Lifecore Biomedical's gross margin?
Lifecore Biomedical's gross margin was 31.4% in fiscal 2026: for every $100 of revenue, Lifecore Biomedical kept $31 after the direct cost of its products and services.
How much does Lifecore Biomedical spend on research and development?
Lifecore Biomedical spent $8.5 million on research and development in fiscal 2026, 6.6% of revenue.
How fast is Lifecore Biomedical growing?
Revenue grew 5.1% a year on average over the last five fiscal years, from $100.9 million to $129.5 million.
What are Lifecore Biomedical's earnings per share?
Lifecore Biomedical earned $-0.78 per diluted share in fiscal 2026, compared with $-1.14 a year earlier.
When does Lifecore Biomedical's fiscal year end?
Lifecore Biomedical's fiscal year ends in May. The latest annual report covers the year ended May 31, 2026 and was filed on March 16, 2026.